following a full submission assessed under the end of life and orphan medicine process:
axicabtagene ciloleucel (Yescarta®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
In a randomised, open-label, phase III study, axicabtagene ciloleucel significantly improved event-free survival compared with standard of care in patients with large B-cell lymphoma.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- axicabtagene ciloleucel (Yescarta)
- SMC ID:
- SMC2628
- Indication:
Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 March 2024